Cargando…
Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways to develop new and alternative therapeutic options to manage the ongoing pandemic. Given circa 7817 licenced compounds available from Compounds Australia that can be screened, this paper demonstrates the utility...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693925/ https://www.ncbi.nlm.nih.gov/pubmed/36366514 http://dx.doi.org/10.3390/v14112417 |
_version_ | 1784837666885337088 |
---|---|
author | McAuley, Alexander J. Jansen van Vuren, Petrus Mohammed, Muzaffar-Ur-Rehman Faheem, Goldie, Sarah Riddell, Shane Gödde, Nathan J. Styles, Ian K. Bruce, Matthew P. Chahal, Simran Keating, Stephanie Blasdell, Kim R. Tachedjian, Mary O’Brien, Carmel M. Singanallur, Nagendrakumar Balasubramanian Viana, John Noel Vashi, Aditya V. Kirkpatrick, Carl M. MacRaild, Christopher A. Shah, Rohan M. Vincan, Elizabeth Athan, Eugene Creek, Darren J. Trevaskis, Natalie L. Murugesan, Sankaranarayanan Kumar, Anupama Vasan, Seshadri S. |
author_facet | McAuley, Alexander J. Jansen van Vuren, Petrus Mohammed, Muzaffar-Ur-Rehman Faheem, Goldie, Sarah Riddell, Shane Gödde, Nathan J. Styles, Ian K. Bruce, Matthew P. Chahal, Simran Keating, Stephanie Blasdell, Kim R. Tachedjian, Mary O’Brien, Carmel M. Singanallur, Nagendrakumar Balasubramanian Viana, John Noel Vashi, Aditya V. Kirkpatrick, Carl M. MacRaild, Christopher A. Shah, Rohan M. Vincan, Elizabeth Athan, Eugene Creek, Darren J. Trevaskis, Natalie L. Murugesan, Sankaranarayanan Kumar, Anupama Vasan, Seshadri S. |
author_sort | McAuley, Alexander J. |
collection | PubMed |
description | The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways to develop new and alternative therapeutic options to manage the ongoing pandemic. Given circa 7817 licenced compounds available from Compounds Australia that can be screened, this paper demonstrates the utility of commercially available ex vivo/3D airway and alveolar tissue models. These models are a closer representation of in vivo studies than in vitro models, but retain the benefits of rapid in vitro screening for drug efficacy. We demonstrate that several existing drugs appear to show anti-SARS-CoV-2 activity against both SARS-CoV-2 Delta and Omicron Variants of Concern in the airway model. In particular, fluvoxamine, as well as aprepitant, everolimus, and sirolimus, has virus reduction efficacy comparable to the current standard of care (remdesivir, molnupiravir, nirmatrelvir). Whilst these results are encouraging, further testing and efficacy studies are required before clinical use can be considered. |
format | Online Article Text |
id | pubmed-9693925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96939252022-11-26 Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection McAuley, Alexander J. Jansen van Vuren, Petrus Mohammed, Muzaffar-Ur-Rehman Faheem, Goldie, Sarah Riddell, Shane Gödde, Nathan J. Styles, Ian K. Bruce, Matthew P. Chahal, Simran Keating, Stephanie Blasdell, Kim R. Tachedjian, Mary O’Brien, Carmel M. Singanallur, Nagendrakumar Balasubramanian Viana, John Noel Vashi, Aditya V. Kirkpatrick, Carl M. MacRaild, Christopher A. Shah, Rohan M. Vincan, Elizabeth Athan, Eugene Creek, Darren J. Trevaskis, Natalie L. Murugesan, Sankaranarayanan Kumar, Anupama Vasan, Seshadri S. Viruses Article The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways to develop new and alternative therapeutic options to manage the ongoing pandemic. Given circa 7817 licenced compounds available from Compounds Australia that can be screened, this paper demonstrates the utility of commercially available ex vivo/3D airway and alveolar tissue models. These models are a closer representation of in vivo studies than in vitro models, but retain the benefits of rapid in vitro screening for drug efficacy. We demonstrate that several existing drugs appear to show anti-SARS-CoV-2 activity against both SARS-CoV-2 Delta and Omicron Variants of Concern in the airway model. In particular, fluvoxamine, as well as aprepitant, everolimus, and sirolimus, has virus reduction efficacy comparable to the current standard of care (remdesivir, molnupiravir, nirmatrelvir). Whilst these results are encouraging, further testing and efficacy studies are required before clinical use can be considered. MDPI 2022-10-31 /pmc/articles/PMC9693925/ /pubmed/36366514 http://dx.doi.org/10.3390/v14112417 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article McAuley, Alexander J. Jansen van Vuren, Petrus Mohammed, Muzaffar-Ur-Rehman Faheem, Goldie, Sarah Riddell, Shane Gödde, Nathan J. Styles, Ian K. Bruce, Matthew P. Chahal, Simran Keating, Stephanie Blasdell, Kim R. Tachedjian, Mary O’Brien, Carmel M. Singanallur, Nagendrakumar Balasubramanian Viana, John Noel Vashi, Aditya V. Kirkpatrick, Carl M. MacRaild, Christopher A. Shah, Rohan M. Vincan, Elizabeth Athan, Eugene Creek, Darren J. Trevaskis, Natalie L. Murugesan, Sankaranarayanan Kumar, Anupama Vasan, Seshadri S. Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection |
title | Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection |
title_full | Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection |
title_fullStr | Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection |
title_full_unstemmed | Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection |
title_short | Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection |
title_sort | use of human lung tissue models for screening of drugs against sars-cov-2 infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693925/ https://www.ncbi.nlm.nih.gov/pubmed/36366514 http://dx.doi.org/10.3390/v14112417 |
work_keys_str_mv | AT mcauleyalexanderj useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT jansenvanvurenpetrus useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT mohammedmuzaffarurrehman useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT faheem useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT goldiesarah useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT riddellshane useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT goddenathanj useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT stylesiank useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT brucematthewp useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT chahalsimran useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT keatingstephanie useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT blasdellkimr useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT tachedjianmary useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT obriencarmelm useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT singanallurnagendrakumarbalasubramanian useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT vianajohnnoel useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT vashiadityav useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT kirkpatrickcarlm useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT macraildchristophera useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT shahrohanm useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT vincanelizabeth useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT athaneugene useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT creekdarrenj useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT trevaskisnataliel useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT murugesansankaranarayanan useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT kumaranupama useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection AT vasanseshadris useofhumanlungtissuemodelsforscreeningofdrugsagainstsarscov2infection |